Novai is a healthcare technology startup that operates in the ophthalmic disease detection and treatment market. The company is developing a novel technology called DARC (Detection of Apoptosing Retinal Cells), which combines a biologic molecule (Annexin-776) with artificial intelligence (AI) to detect and treat eye diseases in real-time. This technology is primarily aimed at pharmaceutical companies and biotech firms involved in drug development for ophthalmic conditions.

Novai's business model revolves around supporting these companies in de-risking and accelerating their clinical trials. The DARC technology aids in early detection of glaucoma, enabling active disease management and improving patient outcomes. Additionally, the company is exploring the use of the DARC biologic molecule as a targeted drug delivery vehicle, which could potentially overcome biological barriers that impede drug delivery to the eye and brain.

The company's technology also offers a unique biomarker that rapidly measures the impact of current and future therapeutics and interventions. This feature helps stratify patients in clinical trials, creating enriched patient cohorts and identifying non-responders to existing and new interventions. This can help pharmaceutical clients avoid ineffective medical management and de-risk their ophthalmic trials.

Novai's technology can be tailored to the unique design of each client, maximizing the success of their glaucoma or AMD (Age-related Macular Degeneration) trial. By delivering DARC in a clearly outlined full-service model, Novai can boost efficiency, quickly determine efficacy, and save clients time and money.

Keywords: Novai, DARC technology, ophthalmic disease detection, glaucoma, artificial intelligence, drug delivery, clinical trials, pharmaceutical clients, biotech firms, AMD.